NCT03754933: A trial that was reported late by GeoVax, Inc.
This trial has reported, although it was 2 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03754933 |
|---|---|
| Title | Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 11, 2019 |
| Completion date | Dec. 29, 2023 |
| Required reporting date | Dec. 28, 2024, midnight |
| Actual reporting date | Dec. 31, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 2 |